Catherine J. Spellicy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Catherine J. Spellicy has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Aleksandar Antanasijevic
Global Health Institute, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
1 shared publication - Alexia Mahy
Laboratory for Biochemical Neuroendocrinology, Department of Human Genetics, KU Leuven, Leuven, Belgium
1 shared publication - Anastasia Theodoropoulou
Laboratory for Biomolecular Modeling, Institute of Bioengineering, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
1 shared publication - Anne Rochtus
UZ Leuven University Hospital, Leuven, Belgium
1 shared publication - Chamindra G. Laverty
Department of Neurosciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA
1 shared publication - David J. Pagliarini
Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri 63110, USA
1 shared publication
Latest Publications
- Open Access
- 10 September 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (17)
Missense variants in CMS22 patients reveal that PREPL has both enzymatic and nonenzymatic functions
Congenital myasthenic syndrome-22 (CMS22, OMIM 616224) is a rare genetic disorder caused by deleterious genetic variation in the prolyl endopeptidase-like ( PREPL ) gene. Previous reports have described patients with deletions and nonsense variants in PREPL , but nothing is known about the effect of missense variants in the pathology of CMS22. In this study, we have functionally characterized missense variants in PREPL from 3 patients with CMS22, all with hallmark phenotypes. Biochemical evaluation revealed that these missense variants do not impair hydrolase activity, thereby challenging the conventional diagnostic criteria and disease mechanism. Structural analysis showed that the variants affect regions most likely involved in intraprotein or protein-protein interactions. Indeed, binding to a selected group of known interactors was differentially reduced for the 3 variants. The importance of nonhydrolytic functions of PREPL was investigated in catalytically inactive PREPL p.Ser559Ala cell lines, which showed that hydrolytic activity of PREPL is needed for normal mitochondrial function but not for regulating AP1-mediated transport in the transgolgi network. In conclusion, these studies showed that CMS22 can be caused not only by deletion and truncation of PREPL but also by missense variants that do not necessarily result in a loss of hydrolytic activity of PREPL.
- 10 September 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (17)
Open AccessMissense variants in CMS22 patients reveal that PREPL has both enzymatic and nonenzymatic functions
Congenital myasthenic syndrome-22 (CMS22, OMIM 616224) is a rare genetic disorder caused by deleterious genetic variation in the prolyl endopeptidase-like ( PREPL ) gene. Previous reports have described patients with deletions and nonsense variants in PREPL , but nothing is known about the effect of missense variants in the pathology of CMS22. In this study, we have functionally characterized missense variants in PREPL from 3 patients with CMS22, all with hallmark phenotypes. Biochemical evaluation revealed that these missense variants do not impair hydrolase activity, thereby challenging the conventional diagnostic criteria and disease mechanism. Structural analysis showed that the variants affect regions most likely involved in intraprotein or protein-protein interactions. Indeed, binding to a selected group of known interactors was differentially reduced for the 3 variants. The importance of nonhydrolytic functions of PREPL was investigated in catalytically inactive PREPL p.Ser559Ala cell lines, which showed that hydrolytic activity of PREPL is needed for normal mitochondrial function but not for regulating AP1-mediated transport in the transgolgi network. In conclusion, these studies showed that CMS22 can be caused not only by deletion and truncation of PREPL but also by missense variants that do not necessarily result in a loss of hydrolytic activity of PREPL.